Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and ...

At the centre of the dermatology market and within the interleukin inhibitor drug class, Sanofi takes a leading position with its blockbuster drug Dupixent (dupilumab), considered as the gold standard ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

The first biologic to enter the COPD market, Dupixent (dupilumab), has paved the way for competitors, demonstrating significant efficacy in reducing exacerbations. Dupixent’s success has highlighted ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

The use of Sanofi’s Dupixent in atopic dermatitis has set a high benchmark for competitors within the space. Credit: marishkaSm via Shutterstock. Sanofi’s participation at the JP Morgan 43rd Annual ...

Sanofi’s chief executive Paul Hudson discussed the success of Dupixent (dupilumab)and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...

Dupixent has been a great drug ... and they were super clear in all secondary parameters too. So, A, the form of a smoker story is pretty interesting from our perspective and orthogonal to ...